Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension
- 1 January 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Medicine
- Vol. 19 (1), 12-17
- https://doi.org/10.2459/jcm.0000000000000590
Abstract
Initial combination therapy with ambrisentan and tadalafil (upfront therapy) offers clinical benefits in pulmonary arterial hypertension (PAH) and reduces the risk of clinical failure compared with monotherapy in naïve patients. The aim of study is to assess the efficacy of a 12-month upfront therapy with ambrisentan and tadalafil in improving haemodynamics in incident PAH patients. This is a multicentre retrospective analysis of real-world Italian clinical data in 56 patients with newly diagnosed PAH. Clinical evaluations, including demographics, medical history, WHO functional class, 6-min walk distance, and right heart catheterization, were collected from the patients’ medical records at baseline and at 12-month follow-up. At baseline, there were 16, 34, and 6 patients in WHO functional class II, III, and IV, respectively. Over a median follow-up of 12 months, 54 (96%) patients were still alive, 6 (11%) of whom received parenteral prostanoids. Ambrisentan–tadalafil combination was associated with significant improvements in WHO functional class (2.2 ± 0.8 vs. 2.8 ± 0.6, P < 0.001, improved in 29 patients), exercise capacity (395 ± 123 vs. 353 ± 101 m, P = 0.039), N-terminal probrain natriuretic peptide (528 ± 493 vs. 829 ± 620 pg/ml; P = 0.009), and haemodynamics (right atrial pressure 7 ± 4 vs. 9 ± 5 mmHg, P = 0.02; mean pulmonary artery pressure 45 ± 15 vs. 50 ± 13 mmHg, P = 0.03; cardiac index 3.0 ± 1.0 vs. 2.5 ± 0.9 l/min/m2, P = 0.001; pulmonary vascular resistance 8 ± 4 vs. 11 ± 6 Wood units, P = 0.001) compared with baseline. Initial combination therapy with ambrisentan and tadalafil offers clinical benefits and significant haemodynamic improvement in newly diagnosed PAH patients.Keywords
This publication has 16 references indexed in Scilit:
- Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trialAnnals Of The Rheumatic Diseases, 2016
- Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- Short‐Term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Long‐Term Survival in Patients with Pulmonary Arterial HypertensionPulmonary Circulation, 2013
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991